Compare FLNT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNT | AARD |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9M | 85.7M |
| IPO Year | 2009 | N/A |
| Metric | FLNT | AARD |
|---|---|---|
| Price | $3.39 | $4.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $3.50 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 220.9K | 123.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,764,000.00 | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $3.35 |
| 52 Week High | $4.15 | $17.94 |
| Indicator | FLNT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 69.96 | 61.92 |
| Support Level | $2.95 | $4.81 |
| Resistance Level | $3.57 | $5.83 |
| Average True Range (ATR) | 0.30 | 0.34 |
| MACD | 0.15 | 0.15 |
| Stochastic Oscillator | 94.57 | 83.43 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.